文献速递腹部泌尿生殖MRPET

神经内分泌肝转移瘤逐病灶评估:个体化MRI序列与68Ga-DOTATATE PET的对比研究

Per-Lesion Assessment of Individual MRI Sequences and 68 Ga-DOTATATE PET in Neuroendocrine Liver Metastases.
PubMed 文献 · Invest Radiol · 2026-07-01

该观察性回顾性研究纳入60例组织学确诊的神经内分泌肿瘤患者,于2017年8月至2023年12月间12周内完成增强MRI与68Ga-DOTATATE PET检查,逐病灶分析1249个病灶(含1050个转移灶)。MRI的敏感度(93% vs 59%,P<0.001)和准确率(93% vs 63%,P<0.001)均优于PET,DWI和肝胆期成像敏感度最高(分别为89%和92%);对于<5 mm转移灶,MRI与PET敏感度分别为81.6%和19.7%。

要点

  • MRI逐病灶检测神经内分泌肝转移瘤的敏感度和准确率均优于68Ga-DOTATATE PET。
  • DWI(敏感度89%)和肝胆期成像(敏感度92%)是MRI中敏感度最高的序列。
  • 对于<5 mm转移灶,MRI敏感度81.6%,PET仅19.7%,MRI优势明显。

核心结论

  • 在逐病灶检测神经内分泌肝转移瘤方面,MRI优于68Ga-DOTATATE PET,其中DWI和肝胆期成像对小的转移灶提供尤其高的敏感度。

研究设计与样本

  • 观察性回顾性研究,纳入60例组织学确诊的神经内分泌肿瘤患者(平均年龄64.9±11.5岁,56.7%男性),于2017年8月至2023年12月间12周内完成增强MRI和68Ga-DOTATATE PET检查,由三名阅片者共识随机顺序评估各MRI序列(DWI、DCE及可用的HBP成像)、完整MRI数据集和PET,参考标准为组织病理学或随访影像。

关键影像表现/征象

  • 动脉期强化见于67.8%的转移灶,门静脉期廓清见于23.7%的转移灶,仅门静脉期廓清显示大小依赖性(<5 mm病灶11.9%至>20 mm病灶55.6%,P<0.01)。
  • PET阴性转移灶小于PET阳性转移灶(5.0 mm vs 8.0 mm,P=0.001),病灶大小与最大标准化摄取值及归一化摄取比相关(r=0.54至0.59,P<0.001)。

诊断标准与关键数值

  • MRI整体敏感度93%、准确率93%;PET整体敏感度59%、准确率63%(P均<0.001)。
  • DWI敏感度89%,HBP成像敏感度92%。
  • 病灶<5 mm时MRI敏感度81.6% vs PET 19.7%;病灶5至10 mm时MRI敏感度96.1% vs PET 61.8%(P<0.001)。

临床应用与阅片要点

  • 逐病灶评估神经内分泌肝转移瘤时应重视DWI和肝胆期成像序列,二者对小转移灶敏感度最高。
  • 对于<5 mm的微小转移灶,PET可能漏诊,MRI尤其是DWI和HBP更具优势。
  • 门静脉期廓清率随病灶增大而升高,小病灶中该征象出现率低(<5 mm者11.9%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To explore magnetic resonance imaging (MRI) and gallium-68 ( 68 Ga)-DOTATATE positron emission tomography (PET) performance in the assessment of neuroendocrine liver metastases (NELMs) on a per-lesion basis, with particular attention to the contribution of individual MRI sequences and assessment of other factors that might influence their detection.

MATERIALS AND METHODS: This observational retrospective study included patients with histologically confirmed neuroendocrine tumors who underwent both contrast-enhanced MRI and 68 Ga-DOTATATE PET within 12 weeks between August 2017 and December 2023. Three readers in consensus assessed individual MRI sequences [diffusion-weighted imaging (DWI), dynamic contrast-enhanced imaging (DCE), and hepatobiliary phase (HBP) imaging when available], entire MRI data set, and PET in random order. The reference standard was histopathology or follow-up imaging. Diagnostic performance metrics were calculated using generalized estimating equations with Bonferroni correction. Correlations were assessed using Pearson correlation coefficients.

RESULTS: A total of 1249 lesions, comprising 1050 metastases, were analyzed in 60 patients (mean age: 64.9±11.5 years; 56.7% male). Compared with PET, MRI demonstrated superior sensitivity (93% vs. 59%, P <0.001) and accuracy (93% vs. 63%, P <0.001), with DWI and HBP providing the highest sensitivity (89% and 92%). Size-stratified analysis showed that MRI outperformed PET, particularly for metastases <5 mm (81.6% vs. 19.7%) and 5 to 10 mm (96.1% vs. 61.8%) ( P <0.001). Arterial enhancement and portal venous washout were present in 67.8% and 23.7% of metastases, respectively, with only portal venous washout showing size dependence (11.9% in <5 mm to 55.6% in >20 mm lesions, P <0.01). PET-negative metastases were smaller than PET-positives (5.0 vs. 8.0 mm, P =0.001), with lesion size correlating with maximum standardized uptake values and normalized uptake ratios ( r =0.54 to 0.59, P <0.001).

CONCLUSIONS: MRI outperformed 68 Ga-DOTATATE PET in detecting NELMs, with DWI and HBP providing particularly high sensitivity for small metastases.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Herold A, Hajati A, Cao Y, et al. Per-Lesion Assessment of Individual MRI Sequences and 68 Ga-DOTATATE PET in Neuroendocrine Liver Metastases. Invest Radiol. 2026. PMID: 41140290. doi:10.1097/RLI.0000000000001248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。